GREENWICH LIFESCIENCES, INC. Stock-Based Compensation
GREENWICH LIFESCIENCES, INC. (GLSI) reported Stock-Based Compensation of $3.03 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-11
- GREENWICH LIFESCIENCES, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $1.48M, a 3.85% decline year-over-year.
- GREENWICH LIFESCIENCES, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $1.54M, a 0.00% change year-over-year.
- GREENWICH LIFESCIENCES, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $2.17M, a 60.31% decline year-over-year.
- GREENWICH LIFESCIENCES, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $1.54M, a 159.74% increase year-over-year.
- GREENWICH LIFESCIENCES, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $6.80M, a 6.20% decline from fiscal 2024.
- GREENWICH LIFESCIENCES, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $7.25M, a 205.01% increase from fiscal 2023.
- GREENWICH LIFESCIENCES, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $2.38M, a 36.37% increase from fiscal 2022.
- GREENWICH LIFESCIENCES, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $1.74M, a 163.99% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $3.03M 10-Q · filed 2026-08-11 | $5.20M derived: sum of 3 quarters · filed 2026-08-11 | $6.74M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $1.54M 10-Q · filed 2026-06-04 | $3.71M derived: sum of 2 quarters · filed 2026-06-04 | $5.26M derived: sum of 3 quarters · filed 2026-06-04 | $6.80M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $2.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $3.71M derived: sum of 2 quarters · filed 2026-06-01 | $5.26M derived: sum of 3 quarters · filed 2026-08-11 | $6.80M 10-K · filed 2026-06-01 |
| 2025-09-30 | $1.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $3.09M derived: sum of 2 quarters · filed 2026-08-11 | $4.63M 10-Q · filed 2025-11-14 | $10.10M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $1.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $3.09M 10-Q · filed 2026-08-11 | $8.56M derived: sum of 3 quarters · filed 2026-08-11 | $9.15M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $1.54M 10-Q · filed 2026-06-04 | $7.01M derived: sum of 2 quarters · filed 2026-06-04 | $7.61M derived: sum of 3 quarters · filed 2026-06-04 | $8.20M derived: sum of 4 quarters · filed 2026-06-04 |
| 2024-12-31 | $5.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $6.06M derived: sum of 2 quarters · filed 2026-06-01 | $6.66M derived: sum of 3 quarters · filed 2026-06-01 | $7.25M 10-K · filed 2026-06-01 |
| 2024-09-30 | $594.52K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $1.19M derived: sum of 2 quarters · filed 2025-11-14 | $1.78M 10-Q · filed 2025-11-14 | $2.38M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $594.52K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $1.19M 10-Q · filed 2025-08-14 | $1.78M derived: sum of 3 quarters · filed 2025-08-14 | $2.38M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $594.52K 10-Q · filed 2025-05-20 | $1.19M derived: sum of 2 quarters · filed 2025-05-20 | $1.78M derived: sum of 3 quarters · filed 2025-05-20 | $2.38M derived: sum of 4 quarters · filed 2025-05-20 |
| 2023-12-31 | $594.52K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $1.19M derived: sum of 2 quarters · filed 2025-04-15 | $1.78M derived: sum of 3 quarters · filed 2025-04-15 | $2.38M 10-K · filed 2025-04-15 |
| 2023-09-30 | $594.52K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $1.19M derived: sum of 2 quarters · filed 2024-11-14 | $1.78M 10-Q · filed 2024-11-14 | $2.38M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $594.52K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $1.19M 10-Q · filed 2024-08-14 | $1.78M derived: sum of 3 quarters · filed 2024-08-14 | $2.54M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $594.52K 10-Q · filed 2024-05-20 | $1.19M derived: sum of 2 quarters · filed 2024-05-20 | $1.95M derived: sum of 3 quarters · filed 2024-05-20 | $2.17M derived: sum of 4 quarters · filed 2024-05-20 |
| 2022-12-31 | $594.52K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-15 | $1.35M derived: sum of 2 quarters · filed 2024-04-15 | $1.58M derived: sum of 3 quarters · filed 2024-04-15 | $1.74M 10-K · filed 2024-04-15 |
| 2022-09-30 | $759.57K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-19 | $984.08K derived: sum of 2 quarters · filed 2023-10-19 | $1.15M 10-Q · filed 2023-10-19 | $1.31M derived: sum of 4 quarters · filed 2023-10-19 |
| 2022-06-30 | $224.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | $389.77K 10-Q · filed 2023-08-21 | $555.20K derived: sum of 3 quarters · filed 2023-08-21 | $720.25K derived: sum of 4 quarters · filed 2023-08-21 |
| 2022-03-31 | $165.27K 10-Q · filed 2023-05-22 | $330.70K derived: sum of 2 quarters · filed 2023-05-22 | $495.75K derived: sum of 3 quarters · filed 2023-05-22 | $660.80K derived: sum of 4 quarters · filed 2023-05-22 |
| 2021-12-31 | $165.43K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $330.48K derived: sum of 2 quarters · filed 2023-03-31 | $495.53K derived: sum of 3 quarters · filed 2023-03-31 | $660.58K 10-K · filed 2023-03-31 |
| 2021-09-30 | $165.05K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $330.10K derived: sum of 2 quarters · filed 2022-11-14 | $495.15K 10-Q · filed 2022-11-14 | $660.20K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $165.05K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $330.10K 10-Q · filed 2022-08-15 | $495.15K derived: sum of 3 quarters · filed 2022-08-15 | $660.20K derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $165.05K 10-Q · filed 2022-05-20 | $330.10K derived: sum of 2 quarters · filed 2022-05-20 | $495.15K derived: sum of 3 quarters · filed 2022-05-20 | $669.10K derived: sum of 4 quarters · filed 2022-05-20 |
| 2020-12-31 | $165.05K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $330.10K derived: sum of 2 quarters · filed 2022-03-21 | $504.05K derived: sum of 3 quarters · filed 2022-03-21 | $677.99K 10-K · filed 2022-03-21 |
| 2020-09-30 | $165.05K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $338.99K derived: sum of 2 quarters · filed 2021-11-15 | $512.94K 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $173.94K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $347.89K 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $173.94K 10-Q · filed 2021-05-20 | |||
| 2019-12-31 | $194.94K 10-K · filed 2021-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |